Evidence map›Paper›PMID 23801600›Full record

ArticleThe Journal of infectious diseases2013

Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi.

Julie Gutman, Dyson Mwandama, Ryan E Wiegand, Doreen Ali, Don P Mathanga, Jacek Skarbinski

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. The Performance of a Rapid Diagnostic Test in Detecting Malaria Infection in Pregnant Women and the Impact of Missed Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Julie GutmanDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia 30322, USA. jgutman@cdc.gov
Dyson Mwandama
Ryan E Wiegand
Doreen Ali
Don P Mathanga
Jacek Skarbinski
Division of Parasitic Diseases and Malaria · USUniversity of Malawi · MWCenters for Disease Control and Prevention · USNational Office for Sanitation of Senegal · SN

Funding

Strengthening National Capacity in Operations ResearchU01CI000189 · CI · UNIVERSITY OF MALAWI · PI BOWIE, CAMERON · 2004 to 2009
$2.0M
Intramural CDC HHS CC999999NCPDCID CDC HHS 5 U01 CI000189NCPDCID CDC HHS U01 CI000189
6 · The paper itself

Abstract

backgroundMalaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae. Despite increasing prevalence of malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recommended for intermittent preventive treatment in pregnancy (IPTp).

methodsWomen without human immunodeficiency virus infection were enrolled upon delivery. Data on the number of SP doses received during pregnancy were recorded. The primary outcome was placental infection demonstrated by histologic analysis. Secondary outcomes included malaria parasitemia (in peripheral, placental, cord blood specimens) at delivery and composite birth outcome (small for gestational age, preterm delivery, or low birth weight). RESULTS.: Of 703 women enrolled, 22% received <2 SP doses. Receipt of ≥ 2 SP doses had no impact on histologically confirmed placental infection. IPTp-SP was associated with a dose-dependent protective effect on composite birth outcome in primigravidae, with an adjusted prevalence ratio of 0.50 (95% confidence interval [CI], .30-.82), 0.30 (95% CI, .19-.48), and 0.18 (95% CI, .05-.61) for 1, 2, and ≥ 3 doses, respectively, compared with 0 doses.

conclusionsIPTp-SP did not reduce the frequency of placental infection but was associated with improved birth outcomes. Few women received no SP, so the true effect of IPTp-SP may be underestimated. Malawian pregnant women should continue to receive IPTp-SP, but alternative strategies and antimalarials for preventing malaria during pregnancy should be investigated.

Indexed as

AdultAntimalarialsDose-Response Relationship, DrugDrug CombinationsFemaleHIV InfectionsHumansInfant, Low Birth WeightInfant, NewbornMalaria, FalciparumMalawiPlacentaPregnancyPregnancy Complications, ParasiticPregnancy OutcomePrevalenceAntimalarialsDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxineintermittent preventive treatmentmalariaMalawipregnancysulfadoxine-pyrimethamine

Identifiers

PMID23801600
PMCPMC4714544
OpenAlexW2165654141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.